Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial-Reference-Cited by-同舟云学术

Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial

Published:2022-06 Issue:5 Volume:13 Page:582-593
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Dal Lago Lissandra,Uwimana Aimé Lambert,Coens Corneel,Vuylsteke Peter,Curigliano Giuseppe,Brouwers Barbara,Jagiello-Gruszfeld Agnieszka,Altintas Sevilay,Tryfonidis Konstantinos,Poncet Coralie,Bottomley Andrew,Sousa Berta,Brain Etienne,Wildiers Hans

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference24 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

3. Treatment of HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015

4. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

5. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comparison of treatment allocation and survival between younger and older patients with HER2-overexpressing de novo metastatic breast cancer;Journal of Geriatric Oncology;2024-07

2. Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy;Frontiers in Cell and Developmental Biology;2024-05-15

3. Metronomic chemotherapy in cancer treatment: new wine in an old bottle;Theranostics;2024

4. Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance;Pharmaceuticals;2023-11-03